Dosage Forms

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

Lipid-based formulations offer a means of addressing the physicochemical and biological challenges of poorly soluble APIs.

Developing Lipid-Based Formulations

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

3D printing is being explored as a manufacturing method for on-demand, personalized medicine.

Considering 3D Printing for Solid Dosage Forms

Senomyx uses an approach, known as taste-blocking, to address the challenges of bitter APIs. Kenneth J. Simone, vice-president of Pharmaceutical Business Development, Senomyx, speaks with Pharmaceutical Technology about this technology. 

Taste-Blocking—An Alternative to Tastemasking

The level of tastemasking required will depend on the API properties and the dosage form design.

Coating for Tastemasking

Paul Kippax is product manager at Malvern Instruments.

Jennifer Burt is applications specialist at Malvern Panalytical.

Carolyn O'Grady is UK applications manager at Malvern Panalytical.

This article examines IVBE testing requirements for topical creams and explores some of the analytical techniques necessary. 

Testing Topicals: Analytical Strategies for the In-Vitro Demonstration of Bioequivalence

Jeff Williamson is director of Product Development at Lonza.

API-in-capsule approaches enable pharmaceutical companies to quickly assess new drug candidates with reduced API consumption and to increase speed to clinic.

Application of API-in-Capsule Best Practices to Accelerate Drug Product Development

Sai V. Nudurupati is assistant director at AbbVie Inc. (North Chicago, IL)

Michael J. Kukulka is senior manager, Global Labeling, Regulatory Affairs, PRA Health Sciences (Deerfield, IL)

Takako Ono is principal scientist, Analytical Development, Pharmaceutical Sciences, Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

Haiyan Grady is associate scientific director CMCC, Takeda Development Center Americas, 300 Massachusetts Ave (4274), Cambridge, MA 02139, Tel: 1-224-554-2067, haiyan.grady@takeda.com

This article describes the approaches used during the development of a dexlansoprazole delayed-release orally disintegrating tablet (ODT) to evaluate tablet size and texture as they relate to disintegration rate and patient experience; in addition, the resistance to alcohol was also characterized. 

Evaluation of Physical Characteristics of Dexlansoprazole Orally Disintegrating Tablets

Jean-Yves Balfin, product manager at Korsch AG, speaks to Pharmaceutical Technology about the ins and outs of multilayer tableting. 

Solid/Semi-Solid Dosage